Polyneuropathy can cause pain, discomfort, and mobility difficulties. Learn more about the types, causes, and symptoms, as well as how to diagnose and treat the condition.

Treatment options for chronic inflammatory demyelinating polyneuropathy include intravenous immunoglobulin, corticosteroids, plasmapheresis (plasma exchange), and a newer medication called Vyvgart ...

Polyneuropathy is a disorder that damages the peripheral nerves. This prevents them from sending regular signals, causing disruptions in communication between your body and brain.

Treatment for chronic inflammatory demyelinating polyneuropathy can include intravenous immunoglobulin, corticosteroids, plasmapheresis, and Vyvgart Hytrulo.

Polyneuropathy Treatment Market Benefiting from Innovations in Neuromodulation Techniques and High Focus on Pain ManagementRockville, MD , Jan. 07, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a ...

Since hATTR with polyneuropathy impacts several organs and is a genetic disease, you’ll likely have to see several specialists to manage the disease. Your care team can include: Genetic counselor.

Peripheral neuropathy (PN), ... As it prepares for WST-057’s final phase, WinSanTor is fast approaching its legacy as the first regenerative treatment for peripheral neuropathy.

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Treatment Side Effects: Peripheral neuropathy and other toxicities may be more common or more severe, leading to dose ...

Netherlands-based argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended its efgartigimod alfa treatment, brand name ...

Lucia Notterpek, Ph.D., professor and senior associate dean for research at the University of Nevada, Reno School of Medicine (UNR Med), has been awarded an Innovation Grants to Nurture Initial ...

--Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in ...